# Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

> **NCT04853043** · PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 7 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT04853043
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-03
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-05-03
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** PI Determination - Slow recruitment, funding concerns, poor response to treatment
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853043, "Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04853043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*